Another Alzheimer’s Drug Hits the Rocks

By Erik Goldman

Pharmaceutical fixes for Alzheimer’s and other forms of dementia are proving very hard to find. The latest drug failure–Axovant Sciences’ once-daily intepirdine–dashes hope in an entire mechanism once thoguht to be important for attenuating dementia.

Remembering Rahmi Oruç Guvenç, PhD

By Erik Goldman

The fields of music and healing lost a true luminary last month, with the passing of Turkish music therapist and researcher, Dr. Rahmi Oruç Guvenç. His death on July 4 from heart failure was reported in the Daily Sabah, a Turkish newspaper. He is survived by his wife and close collaborator, Azize Andrea Guvenç, and […]

Amazon – Whole Foods Merger Highlights Healthy Lifestyle Surge

By Erik Goldman, Editor in Chief

Healthy living is big business. Very big business. Which is why the proverbial 800 lb gorilla just reached for the biggest ripest bunch of organic bananas on the tree. Amazon’s surprise move to acquire the Whole Foods grocery chain for well over $13 billion set the business and financial world aflutter last Friday, with predictions […]

In Memoriam: Fredi Kronenberg, PhD

By Erik Goldman

Holistic Primary Care honors the memory, and celebrates the life and work of Fredi Kronenberg, PhD, a pioneer in the field of botanical medicine and women’s health, who died on April 20. A Stanford-trained physiologist with a deep love and reverence for the natural world, Dr. Kronenberg found her professional niche in the world of […]

Cancer Care Fundamentals for Frontline Clinicians

By Kristen Schepker, Assistant Editor

Today’s rapidly growing population of cancer survivors obliges all frontline clinicians to develop a better understanding of this complex disease, and to learn how to support patients both during and after chemotherapy, radiation and other forms of treatment. Improvements in early detection and better therapies have contributed to a continued increase in the number of […]

Scientific American Calls Out FDA’s Media Malfeasance

By By Erik Goldman, Editor

The Food and Drug Administration uses a system of close-hold news embargoes and “Faustian bargains” to control when and how major media outlets report on the agency’s rulings and other activities, according to a recent article in the venerable Scientific American magazine. In his article titled, “How the FDA Manipulates the Media,” author Charles Seife […]

DEA’s Cannabis Catch-22: Expand Research, Maintain Criminality

By Kristen Schepker, Assistant Editor

Late last summer, the Drug Enforcement Administration (DEA) adopted a new policy designed to foster an increase in medicinal cannabis research. The Administration’s decision opens doors to a larger number of marijuana suppliers qualified to produce cannabis for scientific study, a shift that will arguably lead to broader and more comprehensive study of a drug which, despite widespread medical use throughout the country, remains highly controversial.